Literature DB >> 9496343

Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability.

L R Boots1, S Potter, D Potter, R Azziz.   

Abstract

OBJECTIVE: The measurement of total serum testosterone has an established clinical role in the management of male hypogonadism and female androgen excess disorders. We studied the between-kit variability and precision of six different commercially available testosterone assays and compared them with an established in-house method.
DESIGN: Laboratory observational prospective study.
SETTING: Tertiary university medical center clinical laboratory. PATIENT(S): Three groups of samples each of men (n = 36) and women (n = 15) who had high, normal, or low levels of sex hormone-binding globulin (SHBG), respectively, were studied. INTERVENTION(S): Individual and pooled (male and female) serum samples were analyzed for total testosterone concentration using six different commercially available assays and one in-house method. MAIN OUTCOME MEASURE(S): The between-kit variability and the effect of the mean (+/- SD) SHBG level were determined, the results obtained with the use of the kits and the in-house method were compared, and the intraassay variability (i.e., precision) was evaluated. RESULT(S): Male samples demonstrated a 26.3%-40.8% variance in the results obtained with different kits, which was greatest for samples with the lowest SHBG levels. For female samples, between-kit variability ranged from 57%-115% (average, 77%). The percent deviation of the results obtained with the use of commercial methods from those obtained with the use of our in-house assay was greater for men (mean variance, 194%) than for women (mean variance, 67%). The female pool intraassay coefficient of variation was 3.8% with the use of the in-house method and ranged from 8.9%-21.2% with the use of the commercial kits. The male pool intraassay coefficient of variation was 3.1% with the use of the in-house method and ranged from 3.3%-5.5% with the use of the commercial kits. CONCLUSION(S): Most commercially available kits for measuring the total serum testosterone level demonstrated significant between-kit variability, which was greatest for female samples. Further, samples with the lowest SHBG levels had the highest between-kit variances. These data strongly suggest that the measurement of total serum testosterone using commercial kits may have limited utility, particularly for the detection of hyperandrogenemia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9496343     DOI: 10.1016/s0015-0282(97)00464-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  19 in total

1.  Total testosterone in young men is more closely associated than free testosterone with prostate cancer disparities.

Authors:  Louis Calistro Alvarado
Journal:  Ther Adv Urol       Date:  2011-06

2.  Effect of Metformin on Hormonal and Biochemical Profile in PCOS Before and After Therapy.

Authors:  Bratati Singh; Suchismita Panda; Rachita Nanda; Sanghamitra Pati; Manaswini Mangaraj; Pratima Kumari Sahu; Prakash Chandra Mohapatra
Journal:  Indian J Clin Biochem       Date:  2010-11-19

3.  Association study of CYP17 and HSD11B1 in polycystic ovary syndrome utilizing comprehensive gene coverage.

Authors:  Angela K Chua; Ricardo Azziz; Mark O Goodarzi
Journal:  Mol Hum Reprod       Date:  2012-01-10       Impact factor: 4.025

4.  Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome.

Authors:  Uche Ezeh; Bulent O Yildiz; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

5.  Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.

Authors:  Flaminia Fanelli; Alessandra Gambineri; Marco Mezzullo; Valentina Vicennati; Carla Pelusi; Renato Pasquali; Uberto Pagotto
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

6.  Chronic combined hyperandrogenemia and western-style diet in young female rhesus macaques causes greater metabolic impairments compared to either treatment alone.

Authors:  C A True; D L Takahashi; S E Burns; E C Mishler; K R Bond; M C Wilcox; A R Calhoun; L A Bader; T A Dean; N D Ryan; O D Slayden; J L Cameron; R L Stouffer
Journal:  Hum Reprod       Date:  2017-09-01       Impact factor: 6.918

7.  Impact of obesity on the risk for polycystic ovary syndrome.

Authors:  Bulent O Yildiz; Eric S Knochenhauer; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2007-10-09       Impact factor: 5.958

8.  Small glutamine-rich tetratricopeptide repeat-containing protein alpha (SGTA), a candidate gene for polycystic ovary syndrome.

Authors:  M O Goodarzi; N Xu; J Cui; X Guo; Y I Chen; R Azziz
Journal:  Hum Reprod       Date:  2008-03-10       Impact factor: 6.918

9.  Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.

Authors:  Ning Xu; Kent D Taylor; Ricardo Azziz; Mark O Goodarzi
Journal:  Fertil Steril       Date:  2009-03-26       Impact factor: 7.329

10.  Specificity and predictive value of circulating testosterone assessed by tandem mass spectrometry for the diagnosis of polycystic ovary syndrome by the National Institutes of Health 1990 criteria.

Authors:  Wael A Salameh; Mildred M Redor-Goldman; Nigel J Clarke; Ruchi Mathur; Ricardo Azziz; Richard E Reitz
Journal:  Fertil Steril       Date:  2014-02-15       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.